Novel human monoclonal antibodies specific to the alternatively spliced domain D of Tenascin C efficiently target tumors in vivo

• Hauptverfasser: Lisa Nadal (Verfasst von), Riccardo Corbellari (Verfasst von), Alessandra Villa (Verfasst von), Tobias Weiss (Verfasst von), Michael Weller (Verfasst von), Dario Neri (Verfasst von), Roberto De Luca (Verfasst von)
• Format: Buch
• Veröffentlicht: Taylor & Francis Group, 2020-01-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Antibody-based delivery of bioactive molecules represents a promising strategy for the improvement of cancer immunotherapy. Here, we describe the generation and characterization of R6N, a novel fully human antibody specific to the alternatively spliced domain D of Tenascin C, which is highly express...